MedTrace Logo

OPTIMISE-CKD Drug Utilization

NCT05932901 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2682052

Last updated 2024-04-17

No results posted yet for this study

Summary

This is a multi-national, observational study program using secondary data sources to address research questions related to 1) real-world dapagliflozin utilisation in CKD and potential for further utilisation, 2), the current CKD treatment landscape and 3) real-world effectiveness of dapagliflozin in CKD (pending feasibility assessment).

Conditions

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-04
Primary Completion
2023-09-28
Completion
2023-09-28

Countries

  • United States
  • Japan
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05932901 on ClinicalTrials.gov